All Boards >> Irritable Bowel Syndrome Research Library

View all threads Posts     Flat     Threaded

Pipeline Treatments, Novel Procedures Offer New Options for GI Diseases
      06/04/04 06:41 PM

Reged: 12/09/02
Posts: 7799
Loc: Seattle, WA

CONTACT: Tuesday, May 18, 3:00 pm CDT Kellie Hanzak, 202-955-6222 Jessica Willocks, 301-941-2625

In New Orleans: Morial Convention Center 504-670-6420


Pipeline Treatments, Novel Procedures Offer New Options for GI Diseases

New Orleans, LA – Inflammatory bowel diseases collectively cause significant lifestyle sacrifices and suffering and millions of dollars in related health care costs every year, partially due to a lack of effective diagnostic procedures and therapies. In new studies presented today at Digestive Disease Week in New Orleans, researchers show evidence of accurate and effective new methods for diagnosis, as well as improved treatment options, for sufferers of ulcerative colitis and Crohn's diseases.

Digestive Disease Week (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

"We are pleased to see more attention directed toward improving the lives of people suffering from inflammatory bowel diseases," said Jim Lewis, M.D., of the University of Pennsylvania. "For too long, the rate of discovery was slow. Now we are seeing more answers for the millions of sufferers."

Capsule Endoscopy in IBD: Findings and Effects on Clinical Outcomes (Abstract 105669*)

The M2A video capsule or "camera pill" allows gastroenterologists their best view yet of the small bowel, assisting in the diagnosis of inflammatory bowel disease. Until now, studies have not analyzed the influence of capsule endoscopy on clinical decision-making and therapeutic outcomes in IBD.

According to research presented by scientists from Mount Sinai Medical Center, use of the video capsule improves clinical outcomes significantly.

2 – 2 – 2 Bowel Diseases

For the study, the team of researchers reviewed the results of capsule endoscopy in patients with IBD-related indications. A total of 65 patients met the inclusion criteria and fit in four categories: A) abnormal small bowel series, rule out Crohn's Disease (CD); B) abdominal pain, normal radiologic studies, rule out CD; C) known ulcerative or Crohn's colitis; normal small bowel series and persistent symptoms, rule out small bowel disease; and D) known CD, with persistent obscure bleeding.

Overall, for 20 of the 21 patients (95 percent) in whom major diagnostic findings were discovered using capsule endoscopy, therapeutic decisions based on the results led to clinical improvement in patient outcome. In groups A and B, an absence of small bowel findings in 30 of 32 patients helped rule out CD. Throughout an average follow-up of 19 months, no evidence of CD developed, leading to a negative predictive value for the capsule study of 100 percent in this setting. In groups C and D, researchers discovered positive diagnostic findings on capsule endoscopy in 18 of 33 patients.

"Based on our research, we believe that capsule endoscopy may play an important role in clinical diagnosis and therapeutic decisions in patients with IBD indications," said Peter Legnani, M.D., lead author of the study. "We hope that the ease of use of the capsule may encourage more patients to undergo screening to confirm diagnosis of IBD and receive appropriate treatment."

Basiliximab (anti-CD25) for the Treatment of Steroid Resistant Ulcerative Colitis (Abstract 104640*)

Steroid therapy is one of the most effective treatments for ulcerative colitis (UC), which causes inflammation and ulcers in the lining of the large intestine, but up to 30 percent of patients will have a poor response to steroids. These steroid-resistant individuals present a difficult clinical challenge to gastroenterologists, because few treatment options exist after steroids other than removal of the entire colon (colectomy).

Basiliximab (Simulect®), a novel monoclonal antibody, has potential as a new treatment option, according to research from Henry Wellcome Laboratories at the University of Bristol in England.

3 – 3 – 3 Bowel Diseases

Basiliximab has been proven effective as a steroid sensitizer in steroid resistant UC both in the lab and in humans. This uncontrolled pilot study examined an extended series of 30 steroid resistant UC patients treated with basiliximab. Twenty patients with moderately active disease and 10 patients with severe disease were treated with a single intravenous (IV) dose of basiliximab (40 mg) in addition to their standard steroid therapy to monitor for remission within eight weeks, defined by an Ulcerative Colitis Symptom Score (UCSS) of less than two.

A total of 24 out of the 30 patients (80%) improved their UCSS score, with 19 of 30 (63%) achieving full remission. In the moderate disease group, 14 of 20 patients (70%) achieved full remission, and an additional five of 20 (25%) showed an improvement. In the severe disease group, five of the 10 patients (50%) achieved remission, while five required colectomy. There were no infusion reactions.

"These studies show that the use of basiliximab can provide significant improvements or remission for patients with ulcerative colitis," said Tom Creed, M.D., lead author of the study. "We hope that a larger, controlled trial will confirm these results and help make this potentially valuable therapy available to patients who can benefit from it."

Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Safety and Efficacy Trial of Once-Daily, Oral OPC-6535 in the Treatment of Active Ulcerative Colitis (Abstract 105516*)

For patients suffering from severe ulcerative colitis (UC), new treatments that are safe and have minimal side effects are desperately needed. In this randomized study, researchers at the University of Chicago examined the effectiveness and tolerability of the compound OPC-6535 to treat UC. OPC-6535 was administered orally in a once-daily 25 mg or 50 mg dose to subjects with a new or established diagnosis of UC, flare within 12 weeks, and Disease Activity Index (DAI) of four to 11 on a scale of 12. A total of 186 patients were given either OPC-6535 or placebo for eight weeks. Patients were permitted to take 5-ASA (aminosalicylic acid) if they were stable for 14 days before entry and subsequent study duration (approximately 75% of subjects); 5-ASA is a standard treatment for UC.

4 – 4 – 4 Bowel Diseases

ore than half (55%) of the 25 mg group and 48 percent of the 50 mg group showed clinical improvement. The average change in DAI was significantly greater in the 25 mg group and was nearly statistically significant in the 50 mg OPC-6535 group versus placebo. Improvement in physician global assessment was more noticeable in the 50 mg dosage group, as a significantly higher proportion of these patients achieved remission (DAI 0-1) compared to the other treatment groups.

Responses were uniformly greater in the subgroup of patients with more severe disease. No differences were observed between 5-ASA users and non-users. "Based on these results, we are confident that OPC-6535 could be an effective treatment option for patients with ulcerative colitis, particularly in those with moderately severe disease," said Stephen Hanauer, M.D., lead author of the study.

"Further clinical studies are needed to confirm the best dose, but we were pleased to see a positive response to higher doses, as the efficacy may be even greater." ### Digestive Disease Week (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place May 15-20, 2004 in New Orleans, Louisiana. The meeting showcases approximately 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. *Abstract numbers listed above correlate to abstract ID numbers listed on the DDW Web site, They do not coincide with program numbers as found in the printed DDW Program Guide.

Heather is the Administrator of the IBS Message Boards. She is the author of Eating for IBS and The First Year: IBS, and the CEO of Heather's Tummy Care. Join her IBS Newsletter. Meet Heather on Facebook!

Print     Remind Me     Notify Moderator    

Entire thread
* Inflammatory Bowel Disease
07/14/03 01:51 PM
* Why cannabis relieves IBD symptoms
08/22/18 02:39 PM
* Dietary fiber associated with reduced Crohn's disease flares
01/27/16 02:58 PM
* Probiotics not superior for maintaining ulcerative colitis remission
12/29/15 10:12 AM
* Fecal transplant induces remission in active ulcerative colitis
07/16/15 04:39 PM
* 7 recent developments in Crohn's disease
04/02/15 03:16 PM
* Hormonal contraception improved menstrual-related IBD symptoms
09/15/14 12:43 PM
* Fecal lactoferrin differentiated IBD from IBS
07/29/14 01:50 PM
* Vitamin D and Cancer Risk in IBD
07/15/14 02:53 PM
* Self-assessment scale developed for patients with IBD-fatigue
06/17/14 10:44 AM
* Stool test distinguishes between IBD and IBS
04/07/14 01:40 PM
* Breathing exercises, meditation improved inflammatory markers, quality of life in IBD patients
10/23/13 04:20 PM
* Inflammatory Bowel Disease: Heat Waves Linked to Flares
08/16/13 12:58 PM
* Dietary changes may reduce effects of IBD
06/27/13 05:43 PM
* Genetic Clues May Help Unravel Cause of Crohn's
11/02/12 12:59 PM
* Inflammatory bowel, ulcerative colitis linked to intestinal fungi
06/15/12 01:23 PM
* Smoking makes Crohn's disease worse
05/09/12 01:33 PM
* Kids With Crohn’s Disease, Colitis Often Struggle at School
04/23/12 01:22 PM
* As Nations Develop, So May Bowel Disease
01/09/12 12:01 PM
* Loneliness Triggers Inflammatory Illnesses
02/10/11 10:05 AM
* Infants' antibiotic use tied to IBD risk
11/03/10 01:42 PM
* Olive Oil May Protect Against Ulcerative Colitis
05/05/10 10:32 AM
* Accutane may cause ulcerative colitis
04/09/10 01:38 PM
* Red meat may raise odds for ulcerative colitis, but oily fish could be protective
03/11/10 01:22 PM
* Inflammatory Bowel Disease and Irritable Bowel Syndrome: Separate or Unified?
01/05/10 12:03 PM
* Novel Compound Targets Mucosal Healing in Crohn's
05/29/06 02:19 PM
* Viagra May Help Crohn's Disease
03/04/06 12:50 PM
* Carbon Monoxide Eases Ulcerative Colitis
01/18/06 04:12 PM
* Colonoscopic Surveillance in Inflammatory Bowel Disease
10/11/05 01:33 PM
* Oral Contraceptives and HRT a Risk Factor for Inflammatory Bowel Disease
09/13/05 01:22 PM
* Cannabinoids Show Promise for Inflammatory Bowel Disease
09/01/05 11:23 AM
* Differentiation of Inflammatory Bowel Disease and Irritable Bowel Syndrome
09/01/05 11:13 AM
* The Clinical Epidemiology of Inflammatory Bowel Disease
08/22/05 04:45 PM
* IBD Patients May Benefit From Folic Acid Supplementation
05/22/05 07:02 PM
* Fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis
04/24/05 03:33 PM
* Biotic Therapy Cuts Inflammation in Ulcerative Colitis
02/19/05 05:59 PM
* Calming Crohn's Disease with Fish Oil and Antioxidants
01/07/05 04:55 PM
* Probiotics Prove Just As Effective As a Popular Prescription Drug for Ulcerative Colitis
12/20/04 01:37 PM
* Increased Incidence of Inflammatory Bowel Disease: The Price of the Decline of Infectious Burden?
11/28/04 02:58 PM
* Diet May Influence Relapse in Ulcerative Colitis
10/24/04 07:50 PM
* Parasite Therapy for Crohn's and Colitis?
08/08/04 03:00 PM
* Pipeline Treatments, Novel Procedures Offer New Options for GI Diseases
06/04/04 06:41 PM
* Faulty Gene for Crohn's Disease Found
04/13/04 03:19 PM
* Data links Crohn's disease and antibiotics
02/24/04 02:07 PM
* Elan Reports Successful Results of Antegren Trial for Crohn's Disease
02/10/04 01:30 PM
* 5-ASA Therapy for Inflammatory Bowel Disease No Bar to Colon Cancer
02/10/04 01:29 PM
* Once-Daily Probiotic Treatment Maintains Remission in Ulcerative Colitis patients with Pouchitis
01/26/04 03:33 PM
* Bone Disease and Intestinal Problems May Share a Common Cause
01/07/04 11:47 AM
* Increased Anal Resting Pressure and Rectal Sensitivity in Crohn's Disease
12/16/03 11:59 AM
* Environmental Factors May Play a Role in the Pathogenesis of IBD
12/01/03 05:56 PM
* Colonoscopy Prep
10/17/03 12:05 PM
* Detection of Pulmonary Involvement in Inflammatory Bowel Disease
09/30/03 01:20 PM
* Indeterminate Colitis
09/16/03 03:33 PM
* Familial Occurrence of Inflammatory Bowel Disease in Celiac Disease
09/16/03 03:30 PM
* Bacteria in Milk Linked to Crohn's Disease and Possibly IBS
08/12/03 11:55 AM
* Inflammatory Bowel Disease During Pregnancy.
07/15/03 06:20 PM
* A study of the menopause, smoking, and contraception in women with Crohn's disease.
07/15/03 06:05 PM
* Hormone replacement therapy prevents bone loss in patients with IBD
07/15/03 06:02 PM
* Chemo Drug Improves Crohn's Symptoms
07/14/03 04:09 PM

Extra information
0 registered and 19 anonymous users are browsing this forum.

Moderator:  Heather 

      You cannot post until you login
      You cannot reply until you login
      HTML is enabled
      UBBCode is enabled

Thread views: 321601

Jump to

| Privacy statement Help for IBS Home

UBB.threads™ 6.2 BBB Business Review